Search - tctmd.com

Displaying 121 - 137 of 137

Sort: Relevancy | Date

News Daily News

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

Shelley Wood

February 24, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Industry News

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

November 21, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Aspirin App Pairs Clinical Studies With Technology to Balance Bleeding, Benefits

Michael H. Wilson

June 27, 2016

News Daily News

Experts Agree: Lower Blood Pressure Is Better, but What’s a Realistic Target?

Todd Neale

June 15, 2016

News Daily News

Trial Affirms Aspirin Is Safe to Continue Before Coronary Artery Surgery

Todd Neale

February 25, 2016

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Daily News

Post-TAVR Aspirin Monotherapy No Less Effective, Possibly Safer Than DAPT

May 14, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

News Daily News

Six Months Sufficient for Dual Antiplatelet Therapy

Jason Kahn

October 17, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Daily News

Dabigatran an Alternative to Warfarin for Stroke Prevention in A-Fib Patients

Kim Dalton

September 03, 2009

Advertisement

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Aspirin App Pairs Clinical Studies With Technology to Balance Bleeding, Benefits

Experts Agree: Lower Blood Pressure Is Better, but What’s a Realistic Target?

Trial Affirms Aspirin Is Safe to Continue Before Coronary Artery Surgery

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Post-TAVR Aspirin Monotherapy No Less Effective, Possibly Safer Than DAPT

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Six Months Sufficient for Dual Antiplatelet Therapy

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Dabigatran an Alternative to Warfarin for Stroke Prevention in A-Fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content